Skip to main content
Campaigners blockade AstraZeneca’s HQ to demand it waives patents on its Covid-19 vaccine
Vrotesters gather outside AstraZeneca's HQ in Cambridge to demand that AstraZeneca shares blueprints for its Covid-19 vaccine

SOCIAL JUSTICE campaigners blockaded AstraZeneca’s Cambridge headquarters today to demand that the pharma giant waives patents on its Covid-19 vaccine. 

Two protesters clambered on top of the building’s entrance and held up a sign reading: “People’s vaccine, not profit vaccine,” while another two chained themselves to the doors to prevent people attending the company’s annual meeting. 

The action came ahead of rallies by Global Justice Now outside the Cambridge building, at Oxford University and at AstraZeneca’s Macclesfield site. 

Donate to the Fighting Fund
Support the Morning Star
You have reached the free limit.
Subscribe to continue reading.
More from this author
POLICING THE POLICE: GLC leader Ken Livingstone (centre), wi
Features / 10 March 2023
10 March 2023
In an exclusive investigation, BETHANY RIELLY looks at how the state targeted leading politicians and campaigning groups — labelling many well-known figures 'extremists' and 'subversives' for attempting to hold the police to account
Eritrean female soldiers marching in a parade
Features / 12 December 2022
12 December 2022
On September 4, 16 Eritrean asylum-seekers were arrested at a protest against their country’s dictatorship and its supporters here. Since then, questions have been raised about whether the British authorities are doing enough to protect activists and asylum-seekers from the ‘long arm’ of the regime in Asmara
Similar stories
pockets
Science and Society / 18 December 2024
18 December 2024
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
An electron micrograph of HIV-1 virus particles (colourized
Features / 13 September 2024
13 September 2024
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production